New study tracks Eylea's safety in premature Babies' eye disease
NCT ID NCT05705258
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study follows 75 Japanese babies with retinopathy of prematurity (ROP) who are being treated with Eylea. ROP is an eye condition in premature infants where abnormal blood vessels can damage the retina and lead to blindness. The study aims to collect real-world data on how safe and effective Eylea is by tracking side effects and whether the disease improves or returns within 6 months. No extra tests are required—all information comes from routine doctor visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINOPATHY OF PREMATURITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Many locations
RECRUITINGMultiple Locations, Japan
Conditions
Explore the condition pages connected to this study.